Moolec Science SA income statement

In fiscal 2025, Moolec Science SA reported revenue of $334m, down 28.5% on the year before, operating income of −$104m (a -31.2% margin) and net income of −$111m, or −$17.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Moolec Science SA: income statement, annual
Fiscal year	2023Jun 2023	2024Jun 2024	2025Jun 2025
Revenue	421	466	334
Cost of revenue	235	279	203
Gross profit	185	187	130
Research and development	16	17	15
General and administrative	0	1	0
Operating income	98	19	−104
Interest expense	—	0	—
Income before tax	51	−28	−170
Income tax	−2	1	7
Net income	40	−33	−111
Diluted EPS	$8.80	−$5.61	−$17.25
Diluted shares (average)	34m	38m	—
EBITDA	98	19	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IOVA vs MLEC ARVN vs MLEC ADPT vs MLEC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Moolec Science SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Moolec Science SA.